Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 8/20 | 0.40 |
| ▸ | EP300 | Q09472 | 7/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | RBP4 | P02753 | 5/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21255668 | 0.92 | CREBBP (0.46) | CREBBPEP300BRD4RBP4BAZ2B | |
| SCHEMBL20053806 | 0.85 | CREBBP (0.50) | CREBBPEP300BRD4BAZ2BMAPK1 | |
| SCHEMBL19831875 | 0.84 | CREBBP (0.53) | CREBBPEP300BRD4RBP4MAPK1 | |
| SCHEMBL17234813 | 0.84 | RBP4 (0.45) | CREBBPEP300BRD4RBP4BAZ2B | |
| SCHEMBL17232824 | 0.83 | CREBBP (0.39) | CREBBPEP300BRD4RBP4BAZ2B | |
| SCHEMBL17234776 | 0.82 | RIPK1 (0.43) | CREBBPEP300BRD4MAPK1 | |
| SCHEMBL22958124 | 0.82 | RBP4 (0.38) | CREBBPEP300BRD4RBP4BAZ2B | |
| SCHEMBL18798822 | 0.81 | BAZ2B (0.40) | CREBBPEP300BRD4RBP4BAZ2B | |
| SCHEMBL20952900 | 0.80 | CREBBP (0.41) | CREBBPEP300BRD4RBP4POLB | |
| SCHEMBL19413417 | 0.77 | CREBBP (0.58) | CREBBPEP300BRD4BAZ2BMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407433-B2 | Substituted 4-phenylpiperidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407433-B2 | Substituted 4-phenylpiperidines, their preparation and use | HRH4, HRH3, HRH2 | CREBBP 1412/4885EP300 192/4885BRD4 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.